By Mariam Sunny and Bhanvi Satija Jan 28 (Reuters) - U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion ...
Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...
DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
Eli Lilly (NYSE: LLY) announced a global research collaboration with Seamless Therapeutics to develop programmable gene ...
In a move that continues a recent bolstering of its gene therapy pipeline, Eli Lilly has signed a global research ...
On behalf of Lilly, Seamless will design and programme recombinases that can correct alterations in multiple genes involved ...
A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...
Chinese scientist He Jiankui wants to end Alzheimer’s and thinks Silicon Valley is conducting a “Nazi eugenic experiment.” ...
Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...
Researchers identified AlCas12a, a compact, versatile enzyme that improves CRISPR gene editing and enables faster molecular ...
Researchers developed a topical gene therapy that corrects disease-causing mutations in human skin models using lipid ...
Pneumocystis is an unwieldy genus of fungal pathogens that cause severe pneumonia, particularly in immunocompromised people ...